HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Role of low-dose 2-CdA in refractory or resistant lymphoplasmocytic lymphoma.

Abstract
Cladribrine (2-CdA), a purine analogue active on both dividing and resting lymphocytes, plays an important role in the treatment of indolent lymphoproliferative malignancies such as Hairy Cell Leukemia (HCL), Chronic Lymphocytic Leukemia (CLL), Lymphoplasmocytic Lymphoma (LPL), Waldenström's Macroglobulinemia (WM). With the aim of evaluating the efficacy and toxicity of low dose 2-CdA, 15 lymphoplasmocytic lymphoma patients, not eligible for more aggressive or standard therapies, because of age or poor performance status, were treated with the drug at a dose of 5 mg/m2, once a week for six total courses. All patients showed disease progression. Fourteen patients were valuable for response. In eleven out of these 14 (85.7%) disease progression stopped, with 21% having good hematological responses (one CR and two PR). The treatment was generally well tolerated, without serious infectious events. This schedule may be appropriate for the management of patients where the aim of the treatment is control of disease progression.
AuthorsG Cervetti, S Galimberti, N Cecconi, F Caracciolo, M Petrini
JournalJournal of chemotherapy (Florence, Italy) (J Chemother) Vol. 16 Issue 4 Pg. 388-91 (Aug 2004) ISSN: 1120-009X [Print] England
PMID15332715 (Publication Type: Clinical Trial, Journal Article)
Chemical References
  • Antineoplastic Agents
  • Cladribine
Topics
  • Aged
  • Antineoplastic Agents (administration & dosage, adverse effects)
  • Cladribine (administration & dosage, adverse effects)
  • Dose-Response Relationship, Drug
  • Drug Administration Schedule
  • Drug Resistance, Neoplasm
  • Female
  • Humans
  • Infusions, Intravenous
  • Leukemia, Hairy Cell (diagnosis, drug therapy, mortality)
  • Leukemia, Lymphocytic, Chronic, B-Cell (diagnosis, drug therapy, mortality)
  • Male
  • Middle Aged
  • Probability
  • Prognosis
  • Prospective Studies
  • Risk Assessment
  • Severity of Illness Index
  • Survival Analysis
  • Treatment Outcome
  • Waldenstrom Macroglobulinemia (diagnosis, drug therapy, mortality)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: